Experience

Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500,000 of its newly issued common shares and subscription rights…

Davis Polk advised the underwriter in connection with a $348.9 million SEC-registered offering of 5,263,740 shares of common stock of Teladoc, Inc., consisting of 5,000,000 shares sold by…

Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…

Davis Polk advised the underwriters in connection with an initial public offering of 8,203,332 shares of common stock of Allakos Inc. at $18.00 per share (which includes the exercise in…

Davis Polk advised Auris Medical Holding AG on a public offering of common shares and warrants. The common shares are listed on the NASDAQ Global Market under the symbol “EARS.” Auris…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the NASDAQ…

Davis Polk advised the representatives of the underwriters in connection with the follow-on offering of 5,175,000 shares of common stock for Natera, Inc. for total gross proceeds of …

Davis Polk advised Entera Bio Ltd. on its initial public offering of 1,400,000 ordinary shares and 1,400,000 warrants to purchase up to 700,000 ordinary shares. In addition, Entera Bio Ltd…

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,035,000 shares of common stock of Forty Seven, Inc. Forty Seven’s…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…